Decreased risk of cardiovascular disease mortality associated with occasional positive screens following cancer screenings
Authors:
Open Access
- 14 January 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Abstract
Positive results from cancer screenings, like a cancer diagnosis, can increase the risk of cardiovascular disease (CVD) mortality due to heightened psychological stress. However, positive screening results may also serve as a teachable moment to encourage the adoption of a healthier lifestyle. Consequently, the overall association between positive screenings and CVD mortality risk remains unclear. Based on PLCO data, the risk of CVD mortality associated with the number and types of positive screens was evaluated using Cox regression models among 149,258 eligible participants enrolled between 1993 and 2001. Additional analyses explored these associations stratified by prior CVD history. Exploratory analyses were also conducted to investigate whether positive screens were linked to the potential adoption of a healthier lifestyle. After a median follow-up of 19 years, significantly decreased risk of CVD mortality was observed for individuals with occasional positive screening (≤ 2 positive screens) [adjusted hazard ratio (HR, 95%CIs): 0.931 (0.897–0.968), P < 0.001] compared to the control arm. This effect was particularly notable for flexible sigmoidoscopy [0.842 (0.802–0.884), P < 0.001] and transvaginal ultrasound [0.855 (0.776–0.942), P = 0.002]. However, when the number of positive screens increased to more than two, the reduced risk of CVD mortality became non-significant [0.977 (0.941–1.014), P = 0.220]. Subgroup analyses revealed a greater reduction in CVD mortality risk among participants without a history of CVD [0.917 (0.864–0.973)] compared to those with a history of CVD [0.944 (0.898–0.993)]. Sensitivity analyses excluding screening-detected cancers showed similar association in the overall population [0.933 (0.897–0.970)], as well as in both subgroups with [0.945 (0.898–0.995)] and without previous CVD [0.919 (0.865–0.976)]. Exploratory analyses indicated a significantly higher proportion of any body mass index (BMI) reduction among those with a baseline BMI ≥ 25 kg/m2 who had positive screens compared to the control arm, particularly for individuals with occasional positive screens (48.07% vs. 47.04%, P value = 0.037). Occasional positive cancer screening are associated with reduced risk of CVD mortality, regardless of prior CVD history, cancer diagnosis, and other competitive risks.Keywords
Funding Information
- The Chinese National Key Research and Development Project (2021YFC2500400)
- Tianjin Health Committee Foundation (TJWJ2021MS008)
This publication has 49 references indexed in Scilit:
- Colorectal-Cancer Incidence and Mortality with Screening Flexible SigmoidoscopyNew England Journal of Medicine, 2012
- Suicide and Cardiovascular Death after a Cancer DiagnosisNew England Journal of Medicine, 2012
- Association between low functional health literacy and mortality in older adults: longitudinal cohort studyBMJ, 2012
- Prostate-specific antigen kallikrein and acute myocardial infarction: Where we are. Where are we going?International Journal of Cardiology, 2011
- Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United StatesJNCI: Journal of the National Cancer Institute, 2010
- Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort StudyPLOS Medicine, 2009
- Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular systemEuropean Heart Journal, 2009
- Significant coronary artery disease associated with coronary artery aneurysm and elevation of prostate-specific antigen during acute myocardial infarctionInternational Journal of Cardiology, 2009
- Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screeningCancer, 2005
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialControlled Clinical Trials, 2000